Variational AI, the developer of the Enki generative artificial intelligence (AI) platform for drug discovery, has announced a collaboration with Merck Research Labs under the CQDM Quantum Leap program. Merck will be an early-access user of the Enki Platform, evaluating its capability to generate novel small molecules tailored to specific targets. The Enki Platform operates by using a target product profile (TPP) as prompts to describe molecules in the language of chemistry, rapidly generating structures that meet the TPP.
This approach allows chemists to obtain diverse, selective, and synthesizable lead-like structures in days, streamlining the process of moving into lead optimisation. The collaboration is supported by CQDM to foster beneficial connections between early-stage Canadian companies like Variational AI and global biopharmaceutical organisations such as Merck.
Handol Kim, CEO of Variational AI, emphasised that the Enki Platform eliminates the need for chemists to develop their own generative AI models. Instead, they can submit TPPs and receive tailored structures efficiently, accelerating the drug discovery process. Jesse Paterson, Senior Director of Business Development at CQDM, highlighted the importance of such collaborations for the growth of the Canadian life sciences sector and praised the partnership between Variational AI and Merck.
Click here to read the original news story.